These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 31859348)

  • 21. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
    Chen IC; Hsiao LP; Huang IW; Yu HC; Yeh LC; Lin CH; Wei-Wu Chen T; Cheng AL; Lu YS
    Sci Rep; 2017 Aug; 7(1):9842. PubMed ID: 28852212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
    Lee KM; Guerrero-Zotano AL; Servetto A; Sudhan DR; Lin CC; Formisano L; Jansen VM; González-Ericsson P; Sanders ME; Stricker TP; Raj G; Dean KM; Fiolka R; Cantley LC; Hanker AB; Arteaga CL
    Nat Commun; 2020 Oct; 11(1):5488. PubMed ID: 33127913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.
    Raheem F; Karikalan SA; Batalini F; El Masry A; Mina L
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
    Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
    Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
    Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.
    Pozo-Guisado E; Lorenzo-Benayas MJ; Fernández-Salguero PM
    Int J Cancer; 2004 Mar; 109(2):167-73. PubMed ID: 14750165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
    Miller TW; Rexer BN; Garrett JT; Arteaga CL
    Breast Cancer Res; 2011; 13(6):224. PubMed ID: 22114931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
    Fu X; Osborne CK; Schiff R
    Breast; 2013 Aug; 22 Suppl 2(0 2):S12-8. PubMed ID: 24011769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
    Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
    J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms regulating the hormone sensitivity of breast cancer.
    Tokunaga E; Hisamatsu Y; Tanaka K; Yamashita N; Saeki H; Oki E; Kitao H; Maehara Y
    Cancer Sci; 2014 Nov; 105(11):1377-83. PubMed ID: 25155268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers.
    Ibanez KR; Huang TT; Lee JM
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.